Clinicopathological characteristics in ductal and lobular carcinomas
| IDC n = 411 (%) | ILC n = 43 (%) | p Value | |
|---|---|---|---|
| The p values were assessed by the χ2 test. | |||
| ER, oestrogen receptor; IDC, invasive ductal carcinomas; ILC, invasive lobular carcinoma; PR, progesterone receptor. | |||
| Randomisation | 0.99 | ||
| Tamoxifen | 201(48.9) | 21 (48.8) | |
| Control | 210 (51.1) | 22 (51.2) | |
| Age | 0.49 | ||
| <40 years | 77 (18.7) | 5 (11.6) | |
| 40–49 years | 271 (65.9) | 30 (69.8) | |
| 50–59 years | 63 (15.3) | 8 (18) | |
| Tumour size | 0.47 | ||
| 0–10 mm | 24 (5.8) | 3 (6.9) | |
| 11–20 mm | 133 (32.4) | 10 (23.2) | |
| 21+ mm | 253 (61.5) | 30 (69.8) | |
| Not registered | 1 (0.2) | ||
| Lymph node status | 0.88 | ||
| 0 | 103 (25.0) | 12 (27.9) | |
| 1–3 | 212 (51.6) | 20 (46.5) | |
| 4 | 94 (22.9) | 11 (25.6) | |
| Not registered | 2 (0.5) | ||
| Histological grade | <0.0001 | ||
| I | 47 (11.4) | 1 (2.3) | |
| II | 170 (41.3) | 34 (79.1) | |
| III | 182 (44.3) | 7 (16.3) | |
| Not evaluated | 12 (2.9) | 1 (2.3) | |
| Mitotic index | <0.0001 | ||
| 1 | 120 (29.2) | 30 (69.7) | |
| 2 | 144 (35.5) | 8 (18.6) | |
| 3 | 135 (32.8) | 4 (9.3) | |
| Not evaluated | 12 (2.9) | 1 (2.3) | |
| Ki-67 index | 0.001 | ||
| 0–10% | 161 (39.2) | 25 (58.1) | |
| 11–25% | 105 (25.5) | 5 (11.6) | |
| >25% | 93 (25.5) | 2 (4.6) | |
| Not evaluated | 52 (12.6) | 11 (25.6) | |
| ER status | 0.01 | ||
| Negative | 122 (29.7) | 4 (9.3) | |
| Positive | 275 (66.9) | 33 (76.7) | |
| Not evaluated | 14 (3.4) | 5 (11.6) | |
| PR status | 0.01 | ||
| Negative | 118 (28.7) | 4 (9.3) | |
| Positive | 263 (64.0) | 33 (76.7) | |
| Not evaluated | 30 (7.2) | 6 (13.9) | |